Metastatic platinum-resistant ovarian carcinoma

Clinical trials for Metastatic platinum-resistant ovarian carcinoma explained in plain language.

Never miss a new study

Get alerted when new Metastatic platinum-resistant ovarian carcinoma trials appear

Sign up with your email to follow new studies for Metastatic platinum-resistant ovarian carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug combo targets returned ovarian and uterine cancers

Disease control Ongoing

This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…

Matched conditions: METASTATIC PLATINUM-RESISTANT OVARIAN CARCINOMA

Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 12:33 UTC

Metastatic platinum-resistant ovarian carcinoma

Get alerted when new Metastatic platinum-resistant ovarian carcinoma trials appear

New drug combo targets returned ovarian and uterine cancers